U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

The U.S. induced pluripotent stem cells (iPSCs) market is expected to reach USD 488.42 million by 2031 from USD 218.87 million in 2023, growing at a CAGR of 10.7% in the forecast period of 2024 to 2031.

Market Segmentation
U.S. Induced Pluripotent Stem Cells (iPSCs) Market, By Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Sacffolds, Free-Floating Hydrogel Contructs, and EHTS), Material (Natural Hydrogel Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue To Replace Tissue Destroyed By Infraction Or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others ), Distribution Channel (Direct Tender and Retail Sales) Country (U.S.) – Industry Trends and Forecast to 2031

Overview of U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver

• Technological advancement in regenerative medicine
Restrain

• Safety concerns and technical difficulties

Opportunity

• Increasing interest in personalized medicine

Market Players

Some of the major market players operating in the U.S. induced pluripotent stem cells (iPSCs) market are:

• Corning Incorporated
• Lonza
• MIMETAS
• CN Bio Innovations Ltd
• 3D BIOTEK LLC
• AXOL
• REPROCELL Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.